Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Portable 12V&24V Jump Starter with Lithium lron Phosphate
Contact UsJump Starter featuring advanced lithium iron phosphate technology.
-
Dual station factory test bench
Contact UsThe motor factory test bench, model ZY4800A-2, is a comprehensive test bench for production line general inspection and testing equipment.
-
Pomegranate Powder Extract (Hull) Ellagic Acid
Contact UsLatin Name: Punica granatum L
Synonyms:
Part of Used: Hull
Specifications: Ellagic Acid 80% HPLC
Appearance:
Application:Food Supplements/Nutritional Supplement/Functional Food/Pharmaceutical -
DC Rooftop Mounted Vehicle Air Conditioners
Contact Us● Strong air volume, fast cooling
● Lightweight design, intelligent design
● Longer battery life, meeting the need for a full night’s sleep
● Energy saving/lightweight/quiet
● Split structure, rooftop mounted
● Energy saving and low consumption, quality assurance
● The company has passed the automotive industry IATF16949 certification
Reviews
There are no reviews yet.